Volume 16, Issue 3 (8-2024)                   IJDO 2024, 16(3): 186-190 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Binesh F, Paknejadi S, Namiranian N, Ordooei M. The Erythrocyte Sedimentation Rate in Type 1 Diabetes Mellitus. IJDO 2024; 16 (3) :186-190
URL: http://ijdo.ssu.ac.ir/article-1-888-en.html
Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract:   (244 Views)
Objective: This study aimed to investigate the comparison of the Erythrocyte Sedimentation Rate (ESR) levels in patients with type 1 diabetes mellitus (T1DM) rather than the standard ESR rate as the reference.
Materials and Methods: In this analytical cross-sectional study 80 individuals with T1DM under 14 years of age were selected from Diabetes Research Center from 2021-2022. Sampling was done by available methods. Demographic information such as age, gender, HbA1c, and ESR level was recorded. The collected data were entered into SPSS v.22 software. Pearson correlation was used for association and t-test was used for comparing means. A significance level of P < 0.05 was considered.
Results: thirty three (41.2%) were male and 47 (58.8%) were female. The mean (±SD) age was 9.50 (± 0.414) years. The mean (±SD) ESR in the studied samples was 11.60(±6.475), which had a significant difference with the ESR value of 10 (P= 0.031). Moreover, the ESR of both groups of studied boys -and girls was significantly higher than the standard upper limit of the society (P= 0.0001). Additionally, ESR had a statistical relationship with HbA1c (P= 0.016) and no significant relationship with age (P= 0.730).
Conclusion: ESR levels in children with T1D were significantly elevated, indicating systemic inflammation. ESR also showed a statistical relationship with HbA1c levels, suggesting its potential as a valuable marker for disease activity and management in T1D patients.
 
Full-Text [PDF 415 kb]   (110 Downloads)    
Type of Study: Research | Subject: Special
Received: 2024/04/24 | Accepted: 2024/07/25 | Published: 2024/08/20

References
1. Entezari Z, Injinari N, Vakili M, Namiranian N. Identification of Factors Related to Sexual Dysfunction in Type 2 Diabetic Women. Iranian journal of diabetes and obesity. 2023, 15(2): 66-72. [DOI:10.18502/ijdo.v15i2.12963]
2. Asadollahi S, Hadizadeh M, Namiranian N, Kalantar SM, Firoozabadi AD, Injinari N. Misexpression of LINC01410, FOSL1, and MAFB in peripheral blood mononuclear cells associated with diabetic nephropathy. Gene. 2023;862:147265. [DOI:10.1016/j.gene.2023.147265]
3. Syed FZ. Type 1 diabetes mellitus. Annals of internal medicine. 2022;175(3):ITC33-48. [DOI:10.7326/AITC202203150]
4. Injinari N, Ghoshouni H, Mehrabbeik A, Namiranian N, Ghadiri-Anari A, Azizi R. Comparison of Diabetic Ketoacidosis Characteristics During-and Before the COVID-19 Pandemic. International Journal of Endocrinology and Metabolism. 2023;21(3):134882. [DOI:10.5812/ijem-134882]
5. Gallen I. Type 1 diabetes: clinical management of the athlete. Springer Science & Business Media; 2012. [DOI:10.1007/978-0-85729-754-9]
6. Ordooei M, Niknafs Z, Mehrabbeik A, Namiranian N. Mental and Social Health Status and its Association With Glycosylated Hemoglobin Level in Adolescents Aged 12-18 Years With Type 1 Diabetes. Disease and Diagnosis. 2022;11(2):54-7. [DOI:10.34172/ddj.2022.11]
7. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. European cardiology review. 2019;14(1):50. [DOI:10.15420/ecr.2018.33.1]
8. Cabrera SM, Henschel AM, Hessner MJ. Innate inflammation in type 1 diabetes. Translational Research. 2016;167(1):214-27. [DOI:10.1016/j.trsl.2015.04.011]
9. Ordooei M, Karimi M, Akbarian E, Rasoulizadeh Z. Diabetic ketoacidosis in children before and during COVID-19 pandemic: a cross-sectional study. International Journal of Endocrinology and Metabolism. 2023;21(2). [DOI:10.5812/ijem-132809]
10. Tishkowski K, Gupta V. Erythrocyte sedimentation rate.2020;638-46.http://europepmc.org/books/NBK557485
11. Lapić I, Padoan A, Bozzato D, Plebani M. Erythrocyte sedimentation rate and C-reactive protein in acute inflammation: meta-analysis of diagnostic accuracy studies. American journal of clinical pathology. 2020;153(1):14-29. [DOI:10.1093/ajcp/aqz142]
12. Khaleghi F, Namiranian N, Ansari K, Mansouri M, Injinari N, Aghaeimeybodi F. Relationship between Severity of Primary Lung Involvement with Erythrocyte Sedimentation Rate and Lactate Dehydrogenase in Patients with COVID-19 in Yazd. Journal of Advances in Medical and Biomedical Research. 2022;30(140):215-22. [DOI:10.30699/jambs.30.140.215]
13. Daniels LM, Tosh PK, Fiala JA, Schleck CD, Mandrekar JN, Beckman TJ. Extremely elevated erythrocyte sedimentation rates: associations with Patients' diagnoses, demographic characteristics, and comorbidities. InMayo Clinic Proceedings.2017;92(11):1636-43. [DOI:10.1016/j.mayocp.2017.07.018]
14. Alkaabi J, Sharma C, Yasin J, Afandi B, Beshyah SA, Almazrouei R, et al. Relationship between lipid profile, inflammatory and endothelial dysfunction biomarkers, and type 1 diabetes mellitus: A case-control study. American journal of translational research. 2022;14(7):4838.
15. Korczowski B, Kowalczyk JR, Bijak M, Rusin J. Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2003;15(86):155-7.
16. Guo S, Wang M, Yu Y, Yang Y, Zeng F, Sun F, et al. The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes. BMC Endocrine Disorders. 2020;20:1-8. [DOI:10.1186/s12902-020-00584-7]
17. van Asten SA, Jupiter DC, Mithani M, La Fontaine J, Davis KE, Lavery LA. Erythrocyte sedimentation rate and C‐reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. International wound journal. 2017;14(1):142-8. [DOI:10.1111/iwj.12574]
18. Mottaghi T, Khorvash F, Khorvash F, Maracy M, Kheirrollahi M, Askari G. Association between BMI and inflammation among diabetic polyneuropathy patients. International Journal of Preventive Medicine. 2019;10(1):212. [DOI:10.4103/ijpvm.IJPVM_48_18]
19. Wang Y, Yang P, Yan Z, Liu Z, Ma Q, Zhang Z, et al. The relationship between erythrocytes and diabetes mellitus. Journal of Diabetes Research. 2021;2021(1):6656062. [DOI:10.1155/2021/6656062]
20. Bartholomew's Hospital S, Ecla L. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J. 1983;286(6361):266. [DOI:10.1136/bmj.286.6361.266]
21. Pagana KD, Pagana TJ, Pagana TN. Mosby's Diagnostic & Laboratory Test Reference. 14th edn St. Louis, Mo: Elsevier. 2019.
22. Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R, et al. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes research and clinical practice. 2009;85(1):61-8. [DOI:10.1016/j.diabres.2009.04.016]
23. Satis S. New inflammatory marker associated with disease activity in rheumatoid arthritis: the systemic immune-inflammation index. Current Health Sciences Journal. 2021;47(4):553.
24. Dariya B, Chalikonda G, Srivani G, Alam A, Nagaraju GP. Pathophysiology, etiology, epidemiology of type 1 diabetes and computational approaches for immune targets and therapy. Critical Reviews™ in Immunology. 2019;39(4):239-265. [DOI:10.1615/CritRevImmunol.2019033126]
25. Buschard K. The etiology and pathogenesis of type 1 diabetes-A personal, non-systematic review of possible causes, and interventions. Frontiers in Endocrinology. 2022;13:876470. [DOI:10.3389/fendo.2022.876470]
26. Zorena K, Michalska M, Kurpas M, Jaskulak M, Murawska A, Rostami S. Environmental factors and the risk of developing type 1 diabetes-old disease and new data. Biology. 2022;11(4):608. [DOI:10.3390/biology11040608]
27. Blagov AV, Summerhill VI, Sukhorukov VN, Popov MA, Grechko AV, Orekhov AN. Type 1 diabetes mellitus: Inflammation, mitophagy, and mitochondrial function. Mitochondrion. 2023;72:11-21. [DOI:10.1016/j.mito.2023.07.002]
28. Rogovskii V. Immune tolerance as the physiologic counterpart of chronic inflammation. Frontiers in Immunology. 2020;11:2061. [DOI:10.3389/fimmu.2020.02061]
29. Stanislavovich Rogovskii V. The linkage between inflammation and immune tolerance: interfering with inflammation in cancer. Current cancer drug targets. 2017;17(4):325-32. [DOI:10.2174/1568009617666170109110816]
30. Bikramjit P, Raveender N, Sudipta P. The importance of HbA1C and erythrocyte sedimentation rate as prognostic factors in predicting the outcome of diabetic foot ulcer disease. International Journal of Advances in Medicine. 2017;4(1):137-42. [DOI:10.18203/2349-3933.ijam20170097]
31. Burlaka I. Analysis of apoptotic, clinical, and laboratory parameters in type 1 diabetes and early diabetic nephropathy: clustering and potential groups evaluation for additional therapeutic interventions. Journal of Clinical Research in Pediatric Endocrinology. 2022;14(3):313. [DOI:10.4274/jcrpe.galenos.2022.2022-1-21]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb